Form 4: Nautilus Biotechnology Executive Exercises Options and Sells Shares
SEC Form 4
Mary E. Godwin, Senior VP of Operations at Nautilus Biotechnology, exercised stock options and sold shares on September 23, 2024.
Summary
- On September 23, 2024, Mary E. Godwin, Senior VP of Operations at Nautilus Biotechnology, exercised stock options to acquire 47,031 shares of common stock at a price of $0.46 per share.
- Simultaneously, Ms. Godwin sold 47,031 shares of common stock at a weighted average price of $2.865, with individual sales ranging from $2.80 to $3.02.
- Following these transactions, Ms. Godwin no longer directly owns common stock but continues to hold options for 353,337 shares.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a standard insider transaction, with no clear positive or negative implications for the company's overall prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company executives. It's common for executives to exercise stock options and sell shares for personal financial management.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding executive compensation and stock ownership.
Key Dates
| Date | Description |
|---|---|
| January 21, 2020 | Vesting Commencement Date for the stock options. |
| 09/23/2024 | Date of the stock option exercise and share sale. |
| 01/30/2030 | Expiration date of the stock options. |
| 09/25/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.